Historically, our principal competition comes from existing diagnostic methods used by pathologists and oncologists for existing products, however, increasingly inexpensive sequencing platforms ... may change the competitive landscape.
In addition, companies offering capital equipment and kits or reagents to local pathology laboratories represent another source of potential competition. These kits are used directly by the pathologist, which facilitates adoption more readily than tests like ours that are performed outside the pathology laboratory.
In addition, few diagnostic tests are as expensive as our Onco type DX tests.
We also face competition from companies that offer products or have conducted research to profile genes, gene expression or protein expression in breast, colon or prostate cancer, including public companies such as, GE Healthcare, a business unit of General Electric Company, Hologic, Inc., Myriad Genetics, Inc., NanoString Technologies, Inc., Novartis AG, Qiagen N.V. and Response Genetics, Inc., ...
We face competition from commercial laboratories with strong distribution networks for diagnostic tests, such as Laboratory Corporation of America Holdings and Quest Diagnostics Incorporated.
We may also face competition from Illumina, Inc. and Thermo Fisher Scientific Inc., both of which have announced their intention to enter the clinical diagnostics market.
Other potential competitors include companies that develop diagnostic tests such as Roche Diagnostics ... , Siemens AG and Veridex LLC, a Johnson & Johnson company ...
In our newly established prostate cancer market, we face comparatively greater competition than in our breast cancer market, including competition from products which were on the market prior to our product launch and which are supported by clinical studies and published data. ]
We used to be $22 now we are $13
Its really a dollar thirty $ 1.30
I didnt understand and though I just make something up , I'm sorry
They are ramping up to begin sales sooner than later --
likely small quantities by yea rend,-
We will have both FDA and EU approvals by the end of Q3.2014
That should have been one of gullible and stupid posts that
everyone posted $11 dollars was reasonable
we got a good deal
.could have been 10 like last time
so we got a good deal
LOL. Good one. (ahem)
He got his clients out in the $19. range and he was more or less right about the NTM trial. So, tell me this: are we now closer to Webush's $7.00 OR Piper's $51. ?!?
You KNOW Piper's prolly front-running any offering...shorting for good measure too boot.
Silly me for buying and holding and not trading the stock.
UK ruling, Roche Arbitration, failed BMY HEP clinical trial...
I believe rest of EU will follow suit...with Japan to follow shortly
Global domination of a 250B industry right before our eyes
GILD is slowly becoming a household name with some prominent funds out there...
The only way to play GILD is to be long....
Enjoy the ride my fellow longs!
Patrys to initiate an Investigator-Sponsored
Clinical Trial using PAT-SM6 in combination
with Onyx Pharmaceuticals’ carfilzomib
Combination study with Patrys’ PAT-SM6 and Onyx Pharmaceuticals’ carfilzomib
Trial to be conducted at the University of Würzburg, Germany under the leadership of
Professor Dr. Hermann Einsele, a world-acclaimed expert in blood cancers
Melbourne, Australia; 11 November, 2013: Patrys Limited (ASX: PAB), a clinical stage biotechnology
company has today announced that it is initiating an investigator-sponsored trial (IST) evaluating the
effectiveness of Patrys’ lead anti-cancer drug PAT-SM6 in combination with carfilzomib, in patients
with relapsed and refractory multiple myeloma (MM). The trial will be headed by Professor Dr.
Hermann Einsele, Director of the Department of Medicine II, University of Würzburg, Germany, and
is being funded by Onyx Pharmaceuticals, Inc., an Amgen subsidiary.
Both clinical and preclinical studies of PAT-SM6 conducted to date have shown evidence of activity in
patients with relapsed and refractory MM. One of the notable features of PAT-SM6, being
demonstrated in the currently-ongoing Phase I/IIa clinical trial, is the lack of serious side-effects in
treated patients. This feature of PAT-SM6 may allow it to be safely administered in combination with
carfilzomib and may have the potential to improve current treatments for MM. Carfilzomib is a
proteasome inhibitor owned by Onyx, and is marketed in the United States (U.S.) under the brand
name Kyprolis® (carfilzomib) for Injection. Onyx will provide carfilzomib study drug for the trial.
Hah. They erased Maine's comments or he deleted them. I'll vouch for icono even though no one will believe me and accuse me of being the me person as Icono. We are related and both own Geron shares. He has some certificate Geron shares for which he received the Asterias certificate shares for. My shares are all with a brokerage and I haven't received them in my account yet.
Also, Maine, I wouldn't mess with Icono due to his military background, years of Judo and the fact he can do a lot more pull ups than me considering I am 20 years younger. Less
Reply to Tefferi's Two Hats (Mayo & Geron) by comsensea •8 hours ago
comsensea • 5 hours ago
0users liked this postsusers disliked this posts0Reply
TO Maine and Maine Alternatives (About Dr. T's Geron "hat"): Menlo Park, Calif., August 5, 2014 - Geron Corporation announced today that the company has entered into a transfer agreement with Mayo Clinic whereby the Investigational New Drug (IND) application for imetelstat under which the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST) has been conducted will be transferred from Mayo Clinic to Geron. In addition, Geron will assume sponsorship for the Myelofibrosis IST, and Dr. Ayalew Tefferi will remain the principal investigator for the study. The company and Mayo Clinic have agreed that the IND and sponsorship responsibility for the conduct of the Myelofibrosis IST will be transferred to Geron by September 30, 2014.
4 minutes ago Flag
0users liked this postsusers disliked this posts0Reply
Well yes he is.
Reply to You have a fruad posting on this board too by •May 9, 2014 12:17 PM
24 minutes ago Less
Wall Street ends higher after Ukraine concerns ease
Asian shares edge up, poised for weekly rise
Pershing Square sues U.S. over Fannie Mae, Freddie Mac
‘Hated’ bull market still has room to run
Here we go again? Wall St. buying risky mortgages
JC Penney shares surging as sales reboun
THis is so true.
looks like you choose poorly